Avalo Therapeutics financials
$15.58+3.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $59.0K | $441.0K | $1.9M | $18.1M | $5.4M |
| Gross profit | $59.0K | $807.0K | $640.0K | $14.6M | $3.9M |
| Gross margin | 100.0% | 183.0% | 33.3% | 81.0% | 72.4% |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$82.9M |
| Net margin | −132642.4% | −7965.8% | −1639.5% | −230.8% | −1535.3% |
| Diluted EPS | $-5.84 | $-20.91 | $-113.58 | $-1062.65 | $-2388.00 |
| EBITDA | -$72.6M | -$68.3M | -$23.3M | -$37.3M | -$80.5M |
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Free cash flow | -$51.5M | -$49.1M | -$30.8M | -$26.8M | -$71.0M |
| Diluted shares | 13.4M | 7.5M | 0.3M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $15.9M | $134.5M | $7.4M | $13.2M | $54.6M |
| Short-term investments | $82.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $19.4M | $32.8M |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
| Shareholders' equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology